biphenylylsulfonylamino-3-phenylpropionic acid

biphenylylsulfonylamino-3-phenylpropionic acid (also known as MMP-2/MMP-9 Inhibitor I) is a potent, selective, and orally active small molecule inhibitor of matrix metalloproteinase-2 (MMP-2, gelatinase A) and matrix metalloproteinase-9 (MMP-9, gelatinase B). It was originally developed by Shionogi. The compound acts by binding to the catalytic zinc ion at the active site of these gelatinases, thereby blocking their enzymatic activity. In preclinical research, it has been widely used to investigate the role of MMP-2 and MMP-9 in various pathological processes, including tumor growth, metastasis, blood-brain barrier disruption, and endothelial glycocalyx shedding in diabetic kidney disease and sepsis.

Other names

(2R)-2-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-3-phenylpropionic acid(2R)-2-[(4-biphenylylsulfonyl)amino]-3-phenylpropionic acid444241MMP-2/MMP-9 Inhibitor IMMP-2/MMP-9-IN-1N-([1,1'-biphenyl]-4-ylsulfonyl)-D-phenylalanine